CNI vs NSC

CNI presents a stable financial profile with a Piotroski F-Score of 4/9 and an absent Altman Z-Score, indicating a 'stable' but not 'strong' health trajectory. While the company boasts exceptional operating margins (42.41%) and a strong ROE (22.15%), it is currently trading at a significant premium to its Graham Number ($56.63), though it remains below its growth-based intrinsic value ($133.51). The disconnect between sluggish revenue growth (2.4%) and a high PEG ratio (2.52) suggests the stock may be overvalued relative to its current growth rate. Overall, CNI is a high-quality industrial compounder currently facing valuation headwinds and mediocre short-term financial momentum.

NSC exhibits a stable but mediocre financial health profile with a Piotroski F-Score of 4/9. The stock is severely overvalued, trading at $321.44 despite a Graham Number of $140.92 and an Intrinsic Value of $89.18. This valuation gap is exacerbated by negative year-over-year revenue (-1.70%) and earnings growth (-11.40%), resulting in an unsustainable PEG ratio of 4.12. While operational margins remain strong, the fundamental data suggests the current price is driven by momentum rather than value.